While we highlight a subset of lung cancer patients with SMARCA4 truncating mutations, almost 60% of SMARCA4 alterations were missense mutations, and NSCLC patients with homozygous point mutations also trend towards reduced OS (HR 1.85, P = 0.09; Fig. 2c). This evidence concerns the gene SMARCA4 and lung carcinoma.